Collaborative Practice Agreements

Advanced pharmacy services as part of a CPA are described as collaborative management of drug therapy (CDTM). [a] While traditional practice for pharmacists provides that the legal authority recognizes drug-related problems (DOP) and proposes solutions for PDs to prescription persons (e.g. B physicians), pharmacists who offer CDTMs solve PDs directly when they recognize them. This may include prescribing drugs to select and initiate drugs to treat a patient`s diagnosed illnesses (as described in the CPA), stopping the use of prescription or over-the-counter drugs, and modifying a patient`s drug treatment (for example. B change in strength, frequency, frequency of administration or duration of therapy), evaluation of a patient`s response to drug treatment (including drug treatment). , such as.B. a basic metabolic panel) and the continuation of drug therapy (with a new prescription). [7] In 2010, the American Medical Association (AMA) published a series of reports entitled „AMA Scope of Practice Data Series.“ [61] One report focused on the pharmacy profession, which criticized the formation of CPAs as an attempt by pharmacists to intervene with the physician. In response to the report, a collaboration of seven national pharmacists` associations prepared a response to the WADA Pharmacists Report. [62] The response called on WADA to correct its report and publish the revised report with Errata. [63] In 2011, WADA`s Chamber of Deputies adopted a more flexible tone of the APhA in response to contributions from aPhA and other pharmacists` professional associations and finally adopted the following resolution, which has focused attention on the denial of independent (rather than collaborative or dependent) practical agreements: a Collaborative Practice Agreement (CPA) is a legal document in the United States that establishes a legal relationship between clinical pharmacists and physician collaborators. which allows pharmacists to participate in the CDTM).

According to health researcher Karen E. Koch, the first measure of „collaborative management of drug therapy“ can be attributed to William A.

Comments are closed.

Post Navigation